Natco Pharma’s arm Natco Pharma (Canada) Inc. has reached a settlement with Celgene, which has become a part of Bristol-Myers Squibb, for Lenalidomide capsules in Canada. The terms of the agreement are confidential, as per the agreement, a statement on Friday from Natco Pharma on the settlement said. The drug is the generic of Celgene’s Revlimid indicated in the treatment of multiple myeloma. In 2015, Natco Pharma and its U.S. partner Allergan had reached a settlement with Celgene in a patent infringement case pertaining to Revlimid in the U.S. Under this, Natco is to receive a volume-limited licence to sell Lenalidomide in the U.S. from March 2022 and begin unlimited sale from January 2026.

The Hyderabad-headquartered drugmaker had recently said it was expecting approval for Lenalidomide in the US. Natco Pharma shares closed at ₹679.75 apiece, with a gain of less than 1%.

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Faster pages

Move smoothly between articles as our pages load instantly.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.


A one-stop-shop for seeing the latest updates, and managing your preferences.

Personalised recommendations

A select list of articles that match your interests and tastes.


We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Source link


Please enter your comment!
Please enter your name here